Chief Technology Officer, Codiak Biosciences, Cambridge, MA

During his 30-year career, Konstantin has been at the forefront of development and implementation of advanced biomanufacturing technologies. He has been involved in the commercialization of different therapeutic modalities, including small molecules, monoclonal antibodies, blood factors, enzymes, gene therapy constructs, and exosomes. Over the last decade, he has pioneered the development and large-scale implementation of integrated continuous biomanufacturing, which is becoming a trend for the biotech industry worldwide.

Konstantin is the Chief Technology Officer at Codiak BioSciences in Cambridge, MA, where he is responsible for the development, scale up, manufacturing and characterization of the novel exosome-based biotherapeutics. In parallel, he serves on the Board of Directors of Repligen Corporation. Before Codiak, he was a Vice President of late-stage process and technology development at Genzyme/Sanofi. Prior to that, Konstantin oversaw the Process Sciences organization of Bayer Corp in Berkeley, CA. He received his Ph.D. in Biochemical Engineering from Osaka University, Japan, followed by a post-doctoral assignment at DuPont and the University of Delaware.